SHC

SHC

USD

Sotera Health Company Common Stock

$11.260-0.120 (-1.054%)

实时价格

Healthcare
Diagnostics & Research
美国

价格图表

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$11.380

最高价

$11.435

最低价

$11.160

成交量

0.16M

公司基本面

市值

3.2B

所属行业

Diagnostics & Research

国家/地区

United States

交易统计

平均成交量

1.26M

交易所

NMS

货币

USD

52周价格范围

最低价 $9.53当前价 $11.260最高价 $17.08

AI分析报告

最后更新: 2025年4月27日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

SHC: Sotera Health Company Common Stock - Analyzing Recent Moves & What Might Come Next

Stock Symbol: SHC Generate Date: 2025-04-27 03:51:17

Let's break down what's been happening with Sotera Health (SHC) based on the latest information. We'll look at the news headlines, how the stock price has been acting, and what some predictions are saying.

Recent News Buzz: Analysts Trim Expectations

The news flow for SHC lately seems a bit cautious, mainly centered around analyst views.

  • Just a few days ago, Piper Sandler kept their "Neutral" rating on the stock but decided to lower their price target from $15 down to $13.
  • A bit earlier in April, Barclays also maintained a positive-leaning "Overweight" rating, which sounds good, but they also cut their price target, dropping it from $16 to $12.
  • There was also news about the date for the first-quarter 2025 earnings release. This is just an announcement, not really positive or negative in itself, but it means investors will soon get a clearer picture of the company's financial health.

So, the main takeaway from the analyst news is that while some still see potential (Barclays' "Overweight"), they are becoming less optimistic about how high the stock might go in the near term, lowering those price targets. That's a signal of tempered expectations.

Price Check: A Rough Ride, Then a Small Bounce

Looking at the stock's movement over the past few months tells a story of decline.

  • Back in late January and February, the stock was trading comfortably in the $13 to $14 range.
  • Things took a noticeable turn for the worse around late February and early March, with the price dropping sharply.
  • The slide continued into April, hitting a 52-week low of $9.53 on April 9th. That was quite a drop from where it started the year.
  • However, since hitting that low, the stock has seen a bit of a bounce, trading recently in the $10 to $11 range. The last price we have is around $11.15 (as of April 25th).

Comparing this to the AI's prediction for the next few days, it forecasts a slight dip, predicting negative percentage changes. This suggests the recent bounce might face some pressure soon, potentially pushing the price down a bit from the current level.

Outlook & Ideas: Navigating Mixed Signals

Putting the pieces together – analysts lowering targets, a significant price drop followed by a small bounce, and a near-term AI prediction for a dip – paints a picture that calls for caution right now.

  • The Apparent Near-Term Leaning: The signals are somewhat mixed, but the analyst target cuts and the AI's prediction for the next few days lean towards a cautious or slightly negative outlook in the immediate future. The recent bounce is positive, but it's happening against a backdrop of lowered expectations and predicted near-term weakness. It seems like a "wait and see" situation might be prudent.
  • Potential Entry Consideration: Given the AI predicts a dip and analysts have trimmed targets, jumping in right now might be risky. If someone were considering buying, waiting to see if the predicted dip happens, or waiting for more clarity after the upcoming earnings report, could be a more patient approach. The technical recommendation data from a couple of days ago did suggest entry points around $11.05-$11.12 based on bullish technicals at that time, but the AI's forward-looking prediction for today and tomorrow suggests the price might move away from those levels downwards.
  • Potential Exit/Stop-Loss Consideration: For those already holding the stock, managing risk is key. The technical recommendation data suggested a stop-loss level around $10.60. This is below the last trading price and could serve as a point to consider exiting if the price starts to fall significantly, helping to limit potential losses. Taking profits might be considered if the recent bounce continues unexpectedly, but the AI prediction makes this less likely in the very short term.

Company Context: What SHC Does

Remember, Sotera Health is in the healthcare sector, providing essential sterilization and lab testing services. This is a critical, albeit sometimes complex, part of the healthcare supply chain. The company's fundamentals, like its high debt and high P/E ratio mentioned in the data, are factors that investors often consider alongside price movements and news. These fundamental points might explain some of the caution analysts are showing, despite the essential nature of the business.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can move unexpectedly. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

相关新闻

Analyst Upgrades

Piper Sandler Maintains Neutral on Sotera Health, Lowers Price Target to $13

Piper Sandler analyst Jason Bednar maintains Sotera Health with a Neutral and lowers the price target from $15 to $13.

查看更多
Piper Sandler Maintains Neutral on Sotera Health, Lowers Price Target to $13
GlobeNewswire

Sotera Health Announces First-Quarter 2025 Earnings Release Date

CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the

查看更多
Sotera Health Announces First-Quarter 2025 Earnings Release Date
Analyst Upgrades

Barclays Maintains Overweight on Sotera Health, Lowers Price Target to $12

Barclays analyst Luke Sergott maintains Sotera Health with a Overweight and lowers the price target from $16 to $12.

查看更多
Barclays Maintains Overweight on Sotera Health, Lowers Price Target to $12

AI预测Beta

AI建议

看跌

更新于: 2025年4月28日 21:26

看跌中性看涨

63.5% 置信度

风险与交易

风险等级4/5
高风险
适合于
激进
交易指南

入场点

$11.05

止盈点

$11.38

止损点

$10.60

关键因素

PDI 11.1高于MDI 6.0,且ADX 10.5,表明看涨趋势
当前价格非常接近支撑水平$11.08,表明有强烈的买入机会
交易量是平均值的9.8倍(14,120),表明极强的买入压力
MACD -0.0008高于信号线-0.0051,表明看涨交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。